



NEWS RELEASE

Collectis will be present at the ASCO Annual Meeting

May 27, 2014 – Paris (France) – André Choulika, PhD, CEO of Collectis (Alternext: ALCLS) and Mathieu Simon, MD, Executive Vice President will be attending this year's ASCO meeting in Chicago, IL on May the 30th to June 3rd, 2014.

Disruptive innovation in oncology by gene editing and T cell CARs

Collectis is developing innovative cancer products based on engineered T cells armed with a Chimeric Antigen Receptor (CAR) to target liquid and solid tumors. Collectis' state-of-the-art genome engineering technologies together with the next generation of msCAR and an allogeneic cGMP manufacturing process for CART products take this new paradigm shift in oncology to the next level of the industry. The Company's pipeline focuses on leukemia and solid tumors.

Dr. Choulika & Dr. Simon would welcome the opportunity to meet with you to discuss Collectis' technologies and product pipeline. Engineered allogeneic T cells currently stand out as a genuine therapeutic innovation for treating cancer.

To schedule a convenient time to meet, please contact: secretariat@collectis.com

Disclaimer

This news release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe for shares in Collectis in any country. This news release contains forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve unforeseeable risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements.